Nitric oxide-releasing non steroidal anti-inflammatory drugs: a new generation of anti-tumoral molecules.
Colorectal cancer is the second most common cause of cancer-related mortality in the west. The high incidence and mortality make effective prevention an important public-health and economic issue. The regular intake of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with decreased incidence of certain types of cancer particularly those with an inflammatory component, and then are among the few agents known to be chemopreventive. Nitric oxide-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs) are new chemical entities obtained by adding a nitric oxide-releasing moiety to classical molecules. This new class of molecules has been demonstrated to be much more safe than NSAIDs due to their ability to reduce gastric toxicity. They could therefore represent an alternative to classical NSAIDs treatment. In this review, we sumarise the recent findings in the mechanisms and pathways involved in the antitumoral effects of both NSAIDs and NO-NSAIDs as well as the clinical trials performed with these compounds.
Lavagna
Christian
C
Laboratoire de Gatroentérologie et de Nutrition, Université de Nice Sophia Antipolis. Faculté de Médecine. 28, Ave de Valombrose. 06107 Nice cedex 2, France. clavagna@unice.fr
Del Soldato
Piero
P
Burgaud
Jean-Luc
JL
Rampal
Patrick
P
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D016923:Cell Death / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D009569:Nitric Oxide / Q000378:metabolism*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D009569:Nitric Oxide